Early access granted to Xevudy
Insider Insights

France: Early access granted to Xevudy


The High Authority for Health (Haute Autorité de Santé, HAS) has announced that GSK’s Xevudy (sotrovimab) has been granted early access as a treatment for adults and adolescents aged 12 years and over who are infected with COVID-19 and who present a risk of developing a severe form of the disease. Notably, the early access scheme was reformed with effect from 1st July 2021.

Sources:, “Covid-19: accès précoce accordé au Xevudy® en traitement curative”, 7th January 2021

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.